Compositions and methods of using nintedanib for improving glaucoma surgery success
Compositions and methods of using nintedanib for improving the success rate of glaucoma filtration surgery are disclosed herein. Nintedanib can be used alone or in combination with an anti-metabolite drug in a topical or implant eye formulation.
1. A method for improving success rate of glaucoma surgery, comprising administering to an eye of a subject in need thereof a therapeutically effective amount of axitinib, pazopanib, or regorafenib.
2. The method of claim 1 , wherein the axitinib, pazopanib, or regorafenib is administered in the form of topical eye drop or implant.
3. The method of claim 1 , wherein the amount of axitinib, pazopanib, or regorafenib administered is effective to reduce scar formation or reduce fibrosis at a site of the surgery in the eye of the subject.
4. The method of claim 1 , wherein the amount of axitinib, pazopanib, or regorafenib administered is effective to extend the duration of lower intraocular pressure (TOP), increase either the absolute success rate or the qualified success rate for at least 10 days following glaucoma surgery; or wherein the amount of axitinib, pazopanib, or regorafenib administered is effective to prolong bleb survival.
5. The method of claim 1 , wherein the axitinib, pazopanib, or regorafenib is administered in a form selected from the group consisting of a semi-solid or solid sustained- release implant injected into the eye of the subject.
6. The method of claim 1 , wherein the axitinib, pazopanib, or regorafenib is administered as a topical ocular formulation selected from the group consisting of a solution, suspension, or emulsion.
7. The method of claim 1 , wherein the administration is performed before, during or after glaucoma surgery.
8. The method of claim 1 , wherein the glaucoma surgery is performed using classic trabeculectomy or a method selected from the group consisting of Trabectome, gonioscopy-assisted transluminal trabeculotomy, excimer laser trabeculostomy, and endoscopic cyclophotocoagulation.
9. The method of claim 1 , wherein the glaucoma surgery performed is for implanting an ocular filtration device.
10. The method of claim 9 , wherein the ocular filtration device is an ocular stent.
11. The method of claim 1 , wherein the axitinib, pazopanib, or regorafenib is administered in combination with a cell-proliferation-inhibiting antimetabolite drug.
12. The method of claim 11 , wherein the antimetabolite drug is selected from the group consisting of mitomycin C, 5-fluorouracil, floxuridine, cytarabine, 6-azauracil, azathioprine, methotrexate, mycophenolate mofetil, and thiotepa.
13. A method of adjunctive treatment associated with glaucoma surgery in a subject, the method comprising administering to a subject in need thereof an effective amount of a composition comprising axitinib, pazopanib, or regorafenib.
14. The method of claim 13 , wherein the composition is administered in the form of topical eye drop or implant.
15. The method of claim 13 , wherein the composition contains an amount of axitinib, pazopanib, or regorafenib effective to reduce scar formation or reduce fibrosis at a site of the surgery in the eye of the subject.
16. The method of claim 13 , wherein the composition contains an amount of axitinib, pazopanib, or regorafenib effective to extend the duration of lower TOP, or increase either the absolute or the qualified success rate defined above, for at least 10 days following glaucoma surgery; or wherein the amount of axitinib, pazopanib, or regorafenib administered is effective to prolong bleb survival.
17. The method of claim 13 , wherein the administration of the composition comprising axitinib, pazopanib, or regorafenib is performed before, during or after glaucoma surgery.
18. The method of claim 13 , wherein the composition comprising axitinib, pazopanib, or regorafenib is in either a semi-solid or solid sustained-release implant is injected into the affected eye.
19. The method of claim 13 , wherein the composition comprising axitinib, pazopanib, or regorafenib is administered as a topical ocular formulation selected from a group consisting of a solution, suspension or emulsion.
20. The method of claim 13 , wherein the glaucoma surgery is performed using classic trabeculectomy or a method selected from the group consisting of Trabectome, gonioscopy-assisted transluminal trabeculotomy, excimer laser trabeculostomy, and endoscopic cyclophotocoagulation.
21. The method of claim 13 , wherein the glaucoma surgery performed is for implanting an ocular filtration device.
22. The method of claim 21 , wherein the ocular filtration device is an ocular stent.
23. The method of claim 13 , wherein the composition comprising axitinib, pazopanib, or regorafenib is administered in combination with a cell-proliferation-inhibiting antimetabolite drug.
24. The method of claim 23 , wherein the antimetabolite drug is selected from the group consisting of mitomycin C, 5-fluorouracil, floxuridine, cytarabine, 6-azauracil, azathioprine, methotrexate, mycophenolate mofetil, and thiotepa.
25. The method of claim 1 , wherein the glaucoma surgery performed is a minimally invasive glaucoma surgery.
26. The method of claim 13 , wherein the glaucoma surgery performed is a minimally invasive glaucoma surgery.
27. A method for improving success rate of implanting a stent in glaucoma surgery, comprising administering to an eye of a subject in need thereof a therapeutically effective amount of axitinib, pazopanib, or regorafenib.